LEADER 01550nam  2200481   450 
001 9910544874503321
005 20231114093643.0
010   $a3-030-85109-5
035   $a(MiAaPQ)EBC6884890
035   $a(Au-PeEL)EBL6884890
035   $a(CKB)21078948700041
035   $a(PPN)260825832
035   $a(EXLCZ)9921078948700041
100   $a20220924d2021      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCoronavirus therapeutics$hVolume I$iBasic science and therapy development /$fedited by Alexzander A. A. Asea, Punit Kaur
210  1$aCham, Switzerland :$cSpringer,$d[2021]
210  4$d©2021
215   $a1 online resource (225 pages)
225 1 $aAdvances in Experimental Medicine and Biology ;$vv.1352
311 08$aPrint version: Asea, Alexzander A. A. Coronavirus Therapeutics - Volume I Cham : Springer International Publishing AG,c2022 9783030851088 
410  0$aAdvances in Experimental Medicine and Biology
606   $aCoronaviruses
606   $aCOVID-19$2thub
606   $aTerapčutica$2thub
608   $aLlibres electrňnics$2thub
615  0$aCoronaviruses.
615  7$aCOVID-19
615  7$aTerapčutica
676   $a614.592414
702   $aAsea$b Alexzander A. A.
702   $aKaur$b Punit
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910544874503321
996   $aCoronavirus therapeutics$92917227
997   $aUNINA

LEADER 00893nas  2200337 c 450 
001 9910893224503321
005 20190517095420.0
035   $a(CKB)5280000000196530
035   $a(DE-599)ZDB2440453-6
035   $a(OCoLC)705372800
035   $a(DE-101)989767388
035   $a(EXLCZ)995280000000196530
100   $a20080728a19879999  |y         |
101 0 $ager
135   $auru||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aEKD-Texte$fhrsg. vom Kirchenamt der Evangelischen Kirche in Deutschland
210 31$aHannover$d[1987?]-
300   $aGesehen am 21.02.2019
608   $aMonografische Reihe$2gnd-content
676   $a230
686   $a6,23$2ssgn
801  0$b0003
801  1$bDE-101
801  2$b9001
906   $aJOURNAL
912   $a9910893224503321
996   $aEKD-Texte$94259441
997   $aUNINA